Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy ; volume:5 ; number:1 ; day:17 ; month:10 ; year:2017 ; pages:1-8 ; date:12.2017
Journal for ImmunoTherapy of Cancer ; 5, Heft 1 (17.10.2017), 1-8, 12.2017
- Urheber
-
Jeyakumar, Ghayathri
- Beteiligte Personen und Organisationen
-
Kim, Seongho
Bumma, Naresh
Landry, Craig
Silski, Cynthia
Suisham, Stacey
Dickow, Brenda
Heath, Elisabeth
Fontana, Joseph
Vaishampayan, Ulka
SpringerLink (Online service)
- DOI
-
10.1186/s40425-017-0287-5
- URN
-
urn:nbn:de:1111-20171213878
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jeyakumar, Ghayathri
- Kim, Seongho
- Bumma, Naresh
- Landry, Craig
- Silski, Cynthia
- Suisham, Stacey
- Dickow, Brenda
- Heath, Elisabeth
- Fontana, Joseph
- Vaishampayan, Ulka
- SpringerLink (Online service)
Ähnliche Objekte (12)
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Antiangiogenic therapy
Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Image-based modeling of vascular organization to evaluate anti-angiogenic therapy
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Antiangiogenic therapy
Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Image-based modeling of vascular organization to evaluate anti-angiogenic therapy
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Antiangiogenic therapy
Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Image-based modeling of vascular organization to evaluate anti-angiogenic therapy
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma